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Abstract
Objective. To evaluate the effects of non-pharmacological interventions for primary SS (pSS) on out-
comes falling within the World Health Organization International Classification of Functioning Disability
and Health domains.
Methods. We searched the following databases from inception to September 2014: Cochrane Database
of Systematic Reviews; Medline; Embase; PsychINFO; CINAHL; and clinical trials registers. We included
randomized controlled trials of any non-pharmacological intervention. Two authors independently reviewed
titles and abstracts against the inclusion/exclusion criteria and independently assessed trial quality and
extracted data.
Results. A total of 1463 studies were identified, from which 17 full text articles were screened and
5 studies were included in the review; a total of 130 participants were randomized. The included studies
investigated the effectiveness of an oral lubricating device for dry mouth, acupuncture for dry mouth,
lacrimal punctum plugs for dry eyes and psychodynamic group therapy for coping with symptoms.
Overall, the studies were of low quality and at high risk of bias. Although one study showed punctum
plugs to improve dry eyes, the sample size was relatively small.
Conclusion. Further high-quality studies to evaluate non-pharmacological interventions for PSS are
needed.
Key words: Sjogren’s syndrome, systematic review, non-pharmacological, interventions, rheumatology, fatigue,
dryness, pain, function.
Rheumatology key messages
. This is the first published systematic review of non-pharmacological interventions for primary SS.
. We identified no evidence to support any non-pharmacological interventions to improve primary SS.
. Further quality, appropriately powered randomized controlled trials of non-pharmacological interventions for
primary SS are required.
Introduction
Primary SS (pSS) is a systemic autoimmune disease pri-
marily affecting exocrine glands, resulting in dry eyes and
dry mouth [1]. It has a female preponderance [2], and a
recent meta-analysis has identified a prevalence rate of
74/100 000 inhabitants [2], using the AmericanEuropean
Consensus Criteria [3]. The disease can also have extra-
glandular features, with patients experiencing symptoms
of pain, fatigue, neurological symptoms, sleep disturb-
ance, autonomic dysfunction, low mood and an increased
risk of developing lymphoma [413]. Consequently, many
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patients experience reduced quality of life and difficulty with
carrying out a range of daily activities [14, 15]. Furthermore,
the disease is associated with significant direct and indirect
healthcare costs equating to £1215 000 per patient, per
year [16, 17]. Similar figures have been identified in the USA
[18]. European studies have identified increased physician
visits and higher work disability for patients with a diagnosis
of pSS [11, 19].
Non-pharmacological interventions for pSS may vary
according to the particular symptom that they are target-
ing. They may be complex, target several symptoms at
once and be conducted by more than one member of a
multidisciplinary team [20]. Such interventions may in-
clude fatigue and mood management [11], and patient
education by healthcare professionals [21]. Other inter-
ventions may be conducted by a clinician with specialist
skills (such as occupational therapy to establish a balance
in daily activities and improve function [22]), insertion of
lacrimal punctal plugs for dry eye symptoms [23] or the
use of acupuncture for the symptomatic relief of dry
mouth [24].
Treatments in clinics for people with pSS tend to focus
on pharmacological interventions. However, a recent sys-
tematic review has shown that evidence to support the
efficacy of pharmacological therapies in pSS is poor
[25]. Given the range of bio-psychosocial symptoms that
these patients experience, it is possible that there are ef-
fective non-pharmacological treatments that could im-
prove symptoms. The reduced impact of symptoms
consequently may lead to an improvement in quality of
life, improved work capacity and a reduction in economic
costs to society.The objective of this study was to assess
the effects of non-pharmacological interventions for PSS
in adults.
Methods
All randomized controlled trials (RCTs) were included in
this review. We included adult participants (over the age
of 18 years) with a diagnosis of pSS. All non-
pharmacological interventions that aimed to improve a
symptom or symptoms of pSS were considered for inclu-
sion. Pharmacological interventions are classified as me-
dicinal products in accordance with EU Directive 2001/83/
EEC (EU 2001), and these were excluded from the review.
Homeopathic remedies, herbal medicines and trials of
vitamins were regarded as pharmacological interventions
for the purpose of this review and excluded, as the
claimed mechanism of action is a chemistry change
within the body. Comparison may be a placebo, alterna-
tive intervention that could be pharmacological or non-
pharmacological or usual care. Outcomes considered
within this review fell within the main domains addressed
by the World Health Organization International
Classification of Functioning Disability and Health [26].
Primary outcomes
Primary outcomes included assessments of activities of
daily living, for example, the short-form (SF)-36 physical
functioning scale and the improved HAQ; and participation
outcomes pertaining to work, return to work and social en-
gagement, measured by, for example, The Work and Social
Adjustment Scale.
Secondary outcomes
Impairment of body functions and structures included
outcomes of mood, dryness, disease activity, daytime
sleepiness, fatigue and cognitive function. Environmental
factors included outcomes of costs, carer strain and will-
ingness of employer to adapt work environment. Personal
factors included self-efficacy level of education, adverse
events and quality of life.
Search methods for identification of studies
There are a large number of possible non-pharmacological
interventions, and each may have many synonyms.
Initially, therefore, we performed a search for any RCT or
controlled clinical trial for pSS. We combined the Medical
Subject Headings (MESH) terms and keywords for SS with
the Cochrane Highly Sensitive Search Strategy for iden-
tifying RCTs [27] (see supplementary data, search term
section, available at Rheumatology Online).
The following electronic databases were searched
from inception to September 2014: Cochrane Central
Register of Controlled Trials; Cochrane Database of
Systematic Reviews; Medline via OVID; EMBASE via
OVID; PsychINFO via OVID; CINAHL via EBSCO;
Current Controlled Trials Register (USA); World Health
Organization International Clinical Trials Registry
Platform; The National Research Register Archive (UK);
and The UKCRN Portfolio Database (UK). In addition to
the electronic databases, the references of included stu-
dies were also searched.
Two review authors (K.H. and V.S.) independently
examined the title and abstract of all records identified,
and full papers were retrieved for all papers that seemed
to meet the inclusion criteria. All full-text articles
were screened by two review authors independently
(K.H. and K.D.).
Assessment of risk of bias
Two authors (K.H., K.D.) independently reviewed the stu-
dies for methodological quality, using the Cochrane Risk
of Bias Tool [28]. Any discrepancies were easily resolved
through discussion. Six items were used to assess risk of
bias using only published material. Authors were con-
tacted to seek clarification, but no replies were received,
so a number of items remained unclear.
Results
The 14 publications that were subsequently excluded did
not meet the review inclusion criteria: 8 were not RCTs, 5
did not report the pSS data separately for pSS partici-
pants and 1 study was an abstract only, with no reported
outcomes (supplementary Table S1, available at
Rheumatology Online). Twelve registered relevant clinical
trials are either in process or have not yet published
their findings (supplementary Table S2, available at
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Rheumatology Online). The final selection, based on con-
sensus, resulted in five trials being included in the review
[2933] (Table 1). See Fig. 1 for the flow diagram of
included studies.
Risk of bias in included studies
See Fig. 2 for Risk of Bias Table. Sequence generation
was judged to be at low risk of bias for two studies [32,
33] that used computer-generated randomization
schemes. The method of sequence generation was not
discussed in the remaining three included studies
[2931]. Concealment of allocation was judged to be at
low risk in one study only [33]. Random allocations were
placed in sealed opaque envelopes marked with study
identification numbers by the same clinical staff. The re-
maining four studies did not include a discussion of allo-
cation concealment.
Blinding was a limitation for all of the studies. In none of
them were the participants masked as to the arm of the
study they were in, and the masking was judged to be
high risk. However blinding the participants to the inter-
ventions would have been difficult with the included non-
pharmacological interventions. Detection bias was
deemed to be low in one study [33], in which the staff
performing the assessments and analyses were blinded
to the treatment allocation. Two studies were judged to be
at high risk of detection bias, as the outcome assessors
were not blinded [29, 32]. The remaining two studies did
not mention whether outcome assessors were blinded to
treatment allocation.
Four out of the five included studies were at high risk of
bias from incomplete outcome data. Follow-up measure-
ments were not taken for all of the participants who took
part in one study, and their baseline data were not pre-
sented in the analysis [29]. In a study on punctum plugs,
six participants had spontaneous plug loss and a further
participant had a reaction to the plug; thus, the data from
these seven participants were excluded from the analysis
[32]. Two participants were lost to follow-up in two sep-
arate studies, and their data were excluded from the ana-
lyses [30, 33]. In the remaining study [31], the data
presentation was unclear, and it was not possible to de-
termine whether the analysis was intention to treat.
We did not have access to the study protocols and
were unable to assess this risk; thus, we have reported
the parameter as unclear in four of the studies [3033].
One study was judged to be at high risk of selective re-
porting [29], as an alexithymia measurement was taken
only after treatment in the experimental group and was
compared with baseline measurements from the control
group in the analysis.
Participants
Overall, 130 participants with pSS were included in the
studies. The number of participants with pSS in the stu-
dies ranged from n= 42 [33] to n= 18 [29]. All studies re-
cruited both males and females, but the numbers of males
recruited to each study were low and ranged from n= 1 T
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FIG. 1 Flow diagram of study selection
1226 records idenﬁed 
through database 
searching 
350 addional records 
idenﬁed through 
other sources 
1118 aer duplicates 
removed 
1463 records screened 1446 records excluded 
17 full-text arcles 
assessed for eligibility 
13 relevant registered 
clinical trials, 1 or 
which published 
results in a full-text 
arcle 
12 full-text arcles 
excluded as did not 
meet inclusion criteria 
12 clinical trials have 
not published any 
ﬁndings 
2 further studies
idenﬁed from a 
reference search of 
the included studies 
and full texts retrieved 
2 full-text arcles 
excluded as did not 
meet the inclusion 
criteria 
5 studies included in 
the qualitave analysis 
0 studies included in a 
quantave synthesis 
(meta-analysis) 
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[30] to n= 4 [33], which is representative of the pSS
population.
One study [30] included participants diagnosed with
pSS according to the Copenhagen [34] and San Diego
Criteria [35] and the proposed European Community
Study Group Criteria [36]. The Qiu et al. [33] study re-
ported that participants were diagnosed according to
the AmericanEuropean Consensus Criteria [3]. Mansour
et al. [32] recruited participants diagnosed according to
the European Criteria [36]. The remaining studies [29, 31]
did not specify how the participants were diagnosed, al-
though Frost et al. [31] did specify that they recruited their
participants from a SS clinic (see supplementary Table S3,
available at Rheumatology Online, for a summary of the
main findings of these five selected studies).
Two of the five studies investigated punctum plugs for
dry eyes [32, 33]. One study investigated an intraoral lubri-
cating device for dry mouth [31], another investigated acu-
puncture for dry mouth [30] and the final study
investigated psychodynamic group therapy [29].
A wide range of outcomes was assessed, and this is
reflected in the outcome measures used. Four studies
measured a range of outcomes relating to dryness
[3033]. These included the following clinician-reported
outcomes ofunstimulated salivary flow over 10 min
[3033] and over 15 min [30] and paraffin-stimulated sal-
ivary flow over 5 min [30]. Further clinician-reported as-
sessments of ocular dryness included tear gland function
tests, including Schirmer’s test [32, 33], the Rose Bengal
test, mucus debris in the cul-de-sac [32], tear break-up
time [33], ocular contrast sensitivity, glare disability
and corneal fluorescein staining [33]. Further physician-
reported oral dryness measures included the user of a
113 clinical dryness scale [31], an oral bacteriological
sample and periodontal measurements (pocket depth,
plaque and bleeding) [31]. Participant-reported outcome
measures for dryness included discomfort from mouth
dryness, eye dryness, tongue and mouth burning [10-
point visual analogue scale (VAS)] [30] and subjective
ocular discomfort [32].
Functional outcomes included a participant-reported
questionnaire regarding the ability to speak, chew and
swallow [31]; a 10-point VAS on both perceived global
reduction in activities of daily living and the ability to
chew and swallow [30]. One study used a speech test
where the phoneme sequence PUTTICA was repeated
as many times as possible over a 2-min period [31].
No serious adverse events were reported. One of the
studies on punctum plugs reported spontaneous plug ex-
trusion in 28% of the participants [32].
Effects of interventions
Primary outcomes
Qiu et al. [33] examined glare disability and visual acuity
(ability to discriminate between two objects). Both the arti-
ficial tears and punctal plug groups demonstrated im-
provement for these two outcomes, but there was no
significant difference between the two groups.
Frost et al. [31] examined speech function, but did not
present baseline data; therefore, it is impossible to ascer-
tain whether the difference observed between the two
groups was due to the intervention, as there may have
been a difference at baseline.
Poulsen [29] used the AIMS before and after psycho-
dynamic group therapy. The AIMS is a self-reported ques-
tionnaire on physical functioning. However, the author did
not report the actual results, and we are unable to com-
ment on the reliability of this finding.
List et al. [30] asked patients to report the degree of
reduction on their speech and chewing on a VAS at base-
line and after a 10-week course of acupuncture. There
was no significant difference between the control group
and the intervention group at 10 weeks. In addition, par-
ticipants in the same study were asked to report a global
estimate of the reduction in daily activities on a scale of 0
to 10, with 0 meaning not at all and 10 meaning extreme.
However, again there were no significant differences be-
tween the intervention group and control groups after 10
weeks.
The study by Poulsen [29] was the only one that mea-
sured participation as an outcome, and that study found
no improvement in participation.
FIG. 2 Risk of bias summary: review of authors’ judge-
ments about each risk of bias item for each included study
= low risk of bias = high risk of bias 
= Unknown risk of bias 
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Secondary outcomes
Mansour et al. [32] asked participants to score eye discom-
fort on a 110 scale for both eyes. These measurements
were taken at baseline and at follow-up, 6 weeks after a
silicone punctum plug was inserted into one of the eyes.
However, the scale used was not validated, it was unclear
how the scoring was conducted, and the sample size was
very small (n= 13). The authors did not report the differ-
ences between the control eyes and the plugged eyes.
Despite the small sample size, we have reanalysed their
reported data with a two-tailed unpaired t-test in order to
determine differences between the groups at follow-up.
There were no significant differences between the control
and intervention groups at follow-up (P= 0.2416).
Qiu et al. [33] conducted Schirmer’s test to determine
dryness of the eyes before and after treatment, and both
groups improved; although the authors claim the plug
group improved significantly more than the artificial tear
group, they did not present the analysis that supported
this claim. We have reanalysed their data and can confirm
that it was significant (P< 0.001).
Frost et al. [31] presented no baseline data; therefore,
their results on the use of oral lubrication devices were not
interpretable.
Poulsen [29] reported improvements in alexithymia (dif-
ficulty in identifying and describing emotions) scores 9
months after taking part in psychodynamic group therapy,
despite not measuring the scores at baseline for the inter-
vention group.
List et al. [30] asked participants to evaluate mouth dry-
ness, eye dryness and burning sensation in the mouth on
a VAS at baseline and after a 10-week course of acupunc-
ture, but there were no significant differences between the
intervention and control groups. None of the studies mea-
sured quality of life, self-efficacy or environmental factors
such as carer strain and costs.
Discussion
Overall, the quality of the included studies was poor.
There was high risk of bias in most, and none had con-
ducted power calculations. Furthermore, the sample sizes
used were small, meaning the studies were likely to be
underpowered for detecting an effect size that was pre-
dicted to be modest.
The quality of reporting was also poor; in particular data
presentation, which made data interpretation difficult. For
example, no baseline data were reported in two of the
studies [29, 31], and one of these reported improvements
in an outcome but presented no supporting data [29].
None of the included studies conducted the appropriate
analysis of change in scores, or the analysis of difference
between the two groups. Instead, baseline to study end-
point scores were reported.
Overall, our findings were inconclusive. These studies
suggest that punctal plugs are effective for outcomes of
body function and some activity outcomes. This is in line
with a Cochrane review of punctal plugs in dry eyes [37],
which was not pSS specific. The oral lubrication devices,
psychodynamic therapy and acupuncture did not provide
evidence of significant benefit. However, given the poor
quality of the data presented and the small sample size,
we cannot be certain that these interventions provide no
benefit either.
The studies included some measures of glandular func-
tion, including damage to the eyes and some measures of
activities. Of the activity measures, not all related to every-
day life. An example is the PUTTICA speech test [31],
which is a surrogate outcome with an unclear relationship
to intelligibility or ease of speech. Only one study looked
at any aspects of participation [29], and there appears to
be a lack of appropriate outcome measures that are rele-
vant to patients in terms of activity and participation.
Studies investigating body function and structure out-
comes need to determine the relevance of these out-
comes to patients and to investigate the impact of such
symptoms on participation, the ability to perform daily
activities and quality of life.
We discovered no published reports of RCTs of studies
looking at exercise or cognitive behavioural therapy,
which have been examined in chronic fatigue syndrome
studies [38]. A small study investigating a group aerobic
exercise intervention (Nordic walking) [39] was not eligible
for inclusion, as participants were not randomized and it is
difficult to determine evidence of efficacy in non-
randomized trials [40].
Through a search of clinical trials databases, we were
able to determine that there were 13 relevant clinical trials;
however, only one of these had published results [32]. A
RCT has been registered in the Netherlands, investigating
cognitive behavioural therapy and exercise training to
treat fatigue in SS and non-SS sicca syndrome [41], but
no results have yet been published. Further research is
recommended into clinically relevant non-
pharmacological interventions for which there is evidence
of efficacy in other conditions with similar symptoms; such
as cognitive behavioural therapy and graded exercise
therapy for fatigue management in patients with chronic
fatigue syndrome.
A Cochrane systematic review of punctal plugs for dry
eyes concluded that they provided some symptomatic
relief in severe dry eyes, and it is likely that they would
be of benefit in pSS as well as in other dry patient groups.
Further investigation into any differences between pSS
dry eye treatment and standard dry eye treatment is
warranted.
Conclusion
Overall, we identified no current evidence to support any
non-pharmacological interventions to improve the quality
of life for people with pSS. The area needs good quality,
appropriately powered RCTs that are reported according
to Consolidated Standards of Reporting Trials guidelines.
Outcomes should be sensitive to changes that are
important and relevant to patients.
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